Clinical Trial: Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Share this article:
Clinical Trial: Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma

Sponsor and Collaborators

Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology

Contact
Contact: Jan Walewski, MD   
48-22-546-2223
walewski@coi.waw.pl

Principal Investigator
Study Chair: Jan Walewski, MD

ClinicalTrials.gov Identifier

NCT00937183
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Lymphoma Clinical Trials

Clinical Trial: Safety and Tolerability Study of SNS01-T in Relapsed or Refractory ...

Clinical trial focusing on SNS01-T. Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen ...

Clinical trial focusing on CD20 positive lymphoma and mantle cell lymphoma. Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma

Clinical Trial: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle ...

Clinical trial focusing on temsirolimus, bendamustine, and rituximab. Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma (BERT)